• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    eXoZymes Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    4/2/25 4:30:49 PM ET
    $EXOZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $EXOZ alert in real time by email
    false 0002010788 0002010788 2025-04-02 2025-04-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

    Current Report Pursuant to Section 13 or 15(d) of

    the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported):

    April 2, 2025

     

    EXOZYMES INC.

    (Exact name of registrant as specified in its charter)

     

    Nevada   001-42204   83-4550057

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    750 Royal Oaks Drive, Suite 106

    Monrovia, CA 91016

    (Address of principal executive offices and zip code)

     

    Registrant’s telephone number, including area code: (626) 415-1488

     

    Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Exchange Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock   EXOZ   Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 8.01 — Other Events.

     

    On April 2, 2025, eXoZymes Inc., a Nevada corporation (the “Company”), announced that was holding an investor call to provide fourth quarter and full year 2024 updates.

     

    Item 9.01 – Financial Statements and Exhibits.

     

    (d) Exhibits

     

      Number   Description of Exhibit
           
      99.1   Press Release dated April 2, 2025, announcing the fourth quarter and full year 2024 update
           
      104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     


    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: April 2, 2025 EXOZYMES INC.
         
      By /s/ Fouad Nawaz
        Fouad Nawaz,
        Vice President, Finance

     

     

     

    Get the next $EXOZ alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EXOZ

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $EXOZ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Rayo Edgardo Javier claimed ownership of 77,909 shares (SEC Form 3)

      3 - EXOZYMES INC. (0002010788) (Issuer)

      3/25/25 5:14:08 PM ET
      $EXOZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXOZ
    Financials

    Live finance-specific insights

    See more
    • eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO

      Expanded leadership team as eXoZymes ramps up commercial growth Damien Perriman brings more than two decades of experience in successfully developing and commercializing novel biotechnologies Focus on developing commercial opportunities, spin-outs, joint-ventures, and licensing deals with future partners Monrovia, CA, April 02, 2025 (GLOBE NEWSWIRE) -- Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels - announced the appointment of Damien Perriman to a newly created role as Chief Commercial Officer (CCO). Perriman brings more than two decades of experience i

      4/2/25 4:10:00 PM ET
      $EXOZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • eXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025

      Monrovia, CA , March 26, 2025 (GLOBE NEWSWIRE) -- eXoZymes Inc. (NASDAQ:EXOZ) ["eXoZymes"] - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels - plans to host a webinar on Wednesday, April 2, 2025 at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter and full year 2024. A press release detailing these results will be issued prior to the call. Michael Heltzen, CEO of eXoZymes will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer period. Investors can pre-regi

      3/26/25 5:00:00 PM ET
      $EXOZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXOZ
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bringing clarity and precision to the cell-free space by introducing exozymes

      Scientific definition of exozymes featured as cover story in GEN Biotechnology, freely available as an Open Access paper The author team introduces the terms ‘exozymes' to bring clarity to the rapidly evolving field of cell-free biomanufacturing—a biomanufacturing method to produce chemicals without relying on living cells like bacteria or yeast The paper features co-authors from multiple institutions such as The National Renewable Laboratory (NREL), UCLA, Caltech, University of Colorado Boulder, Sepia Biosciences, as well as the venture studio, Ferment  The authors intend the terms to be freely available for use by the broader scientific community, and no trademarks have been filed Mon

      4/21/25 4:10:00 PM ET
      $EXOZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant

      Monrovia, CA, April 10, 2025 (GLOBE NEWSWIRE) -- Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced its latest initiative - BioClick - a pioneering concept designed to enhance and accelerate the engineering of enzymes for advanced chemical reactions. Funded in part by a $300K grant from the National Institutes of Health (NIH), this project has the potential to revolutionize how medicines and other bio-based compounds are created. At the heart of BioClick is a focus on group transfer reactions, a class of biochemical reactions that allow enzym

      4/10/25 4:30:00 PM ET
      $EXOZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO

      Expanded leadership team as eXoZymes ramps up commercial growth Damien Perriman brings more than two decades of experience in successfully developing and commercializing novel biotechnologies Focus on developing commercial opportunities, spin-outs, joint-ventures, and licensing deals with future partners Monrovia, CA, April 02, 2025 (GLOBE NEWSWIRE) -- Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels - announced the appointment of Damien Perriman to a newly created role as Chief Commercial Officer (CCO). Perriman brings more than two decades of experience i

      4/2/25 4:10:00 PM ET
      $EXOZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXOZ
    SEC Filings

    See more
    • SEC Form 10-Q filed by eXoZymes Inc.

      10-Q - EXOZYMES INC. (0002010788) (Filer)

      5/12/25 2:34:24 PM ET
      $EXOZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by eXoZymes Inc.

      S-8 - EXOZYMES INC. (0002010788) (Filer)

      4/25/25 6:19:15 AM ET
      $EXOZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B3 filed by eXoZymes Inc.

      424B3 - EXOZYMES INC. (0002010788) (Filer)

      4/7/25 5:29:24 PM ET
      $EXOZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care